Dr.ย Tae Wonย Kim
MD, PhD
Professor of Medical Oncology
corporate_fareAsan Medical Center, Seoul, South Korea
Tae Won Kim
MD, PhD
Prof. Tae Won Kim is a Professor of Medical Oncology at Asan Medical Center and the University of Ulsan College of Medicine in Seoul, one of South Korea's most respected cancer institutions. He is a globally recognised expert in colorectal and gastrointestinal oncology with over 20 years of clinical and research experience.
Prof. Kim's clinical work is concentrated on advanced colorectal cancer, rectal cancer, and molecularly defined subgroups including MSI-H and dMMR tumours, where immunotherapy offers meaningful benefit. His departmental affiliations span the Colorectal Cancer Center, Digestive Disease Center, AMC Cancer Institute, and the Center for Personalized Cancer Medicine, reflecting his multidisciplinary approach. He has held leadership roles as Vice-President of the Korean Cancer Association, Chairman of the Korean Society of Medical Oncology, and Editor-in-Chief of Clinical Colorectal Cancer. A postdoctoral fellowship at the University of Chicago trained him in leading research environments, and he remains an active ASCO and ESMO presenter, contributing to international colorectal cancer guidelines and trial evidence.
CancerFax can coordinate medical-report review and consultation support for international patients seeking an opinion from Prof. Kim at Asan Medical Center, subject to case acceptance and hospital availability.
Why Consider Prof. Tae Won Kim?
Prof. Kim is one of Asia's foremost authorities on colorectal cancer treatment, combining a 20-year academic oncology career with active clinical trial leadership and international research recognition.
Areas of Specialisation
Advanced colorectal and gastrointestinal oncology with a focus on molecular precision
Prof. Kim's specialisation centres on medically treating colorectal, rectal, and broader gastrointestinal cancers. His work encompasses anti-EGFR therapy, VEGF-targeted agents, immunotherapy for MSI-H disease, pharmacogenetics, and the clinical development of novel drug combinations.
Colorectal & Rectal Cancer
Comprehensive systemic therapy for localised, locally advanced, and metastatic colorectal and rectal cancers.
- arrow_rightFOLFOX, FOLFIRI, CAPOX-based regimens for first- and second-line disease
- arrow_rightAnti-EGFR therapy (cetuximab, panitumumab) for RAS/BRAF wild-type tumours
- arrow_rightAnti-VEGF therapy (bevacizumab, ramucirumab) selection and sequencing
- arrow_rightBiomarker-driven treatment planning including RAS, BRAF, HER2, and MSI testing
- arrow_rightNeoadjuvant and adjuvant systemic therapy in combination with radiotherapy planning
- arrow_rightMultidisciplinary coordination with surgical and radiation oncology teams
MSI-H & Immunotherapy
Checkpoint inhibitor strategies for microsatellite-instability-high and mismatch repair-deficient colorectal cancer.
- arrow_rightPembrolizumab (KEYNOTE-177) and nivolumab for first- and second-line MSI-H/dMMR mCRC
- arrow_rightDurvalumab for MSI-H or POLE-mutated metastatic colorectal cancer โ clinical trial experience
- arrow_rightBiomarker assessment: MMR IHC, MSI-PCR, and comprehensive genomic profiling
GI Oncology & Pharmacogenetics
Broader gastrointestinal cancer management and pharmacogenetic-guided systemic therapy.
- arrow_rightMedical oncology management of gastric, small bowel, and anal canal cancers
- arrow_rightSystemic therapy coordination within multidisciplinary GI oncology teams
- arrow_rightIrinotecan toxicity prediction based on UGT1A1 genotyping
- arrow_rightPharmacogenetic profiling to guide chemotherapy selection and dosing
Procedures & Treatment Approaches
Systemic therapy, immunotherapy, and precision oncology for colorectal and GI cancers
Prof. Kim's clinical practice covers the full range of medical oncology interventions for colorectal and gastrointestinal cancers, from molecularly guided first-line treatment through to second opinions and clinical trial pathways.
Colorectal Cancer Systemic Therapy
Medical OncologyEvidence-based chemotherapy and targeted agent regimens for all stages of colorectal cancer.
Targeted Therapy
Targeted TherapyMolecularly guided anti-EGFR and anti-VEGF therapy tailored to tumour biomarker profile.
Immunotherapy for MSI-H CRC
Medical OncologyCheckpoint inhibitor-based treatment for MSI-H and dMMR metastatic colorectal cancer.
Molecular Diagnostics & Staging
DiagnosisComprehensive biomarker assessment prior to treatment planning.
Second Opinion Consultations
Second OpinionExpert independent review of colorectal cancer diagnosis and treatment plans.
Research & Publications
International clinical trial leadership and peer-reviewed contributions in colorectal oncology
Prof. Kim is a prolific contributor to colorectal cancer research, with publications in SCI/SCIE journals and an active role in global clinical trials. He is the responsible party for the Asan Medical Center-sponsored durvalumab trial in MSI-H or POLE-mutated metastatic colorectal cancer (NCT03435107).
Prof. Kim's active clinical trial leadership at Asan Medical Center means eligible patients may be considered for access to investigational therapies. CancerFax can coordinate case submission and eligibility assessment, subject to trial availability.
Education & Training
Prof. Kim completed his medical training at Seoul National University and the University of Ulsan, followed by speciality training in oncology at Asan Medical Center and an international postdoctoral fellowship at the University of Chicago, USA.
Clinical Experience
Prof. Kim has built a 20-year career at Asan Medical Center, progressing from clinical instructor to full professor while maintaining an internationally active research and academic profile.
Languages & International
Prof. Kim conducts consultations in the following languages.
CancerFax can coordinate professional medical interpreter support for international patients who require assistance beyond English and Korean.
CancerFax can coordinate professional medical interpreter support for patients consulting in other languages.
How CancerFax Helps You Access Dr. Tae Won Kim
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Tae Won Kim's team โ with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history โ prepared as a structured clinical summary for Dr. Tae Won Kim's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Tae Won Kim before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Tae Won Kim's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Tae Won Kim's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Tae Won Kim's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Prof. Tae Won Kim
Asan Medical Center in Seoul receives international patients from across Asia and beyond. CancerFax can coordinate medical-report submission and consultation support for international patients seeking an opinion from Prof. Kim, subject to hospital availability and case acceptance.
Prof. Kim specialises primarily in colorectal cancer (colon and rectal cancer), including advanced and metastatic disease. He has particular expertise in MSI-H and dMMR colorectal cancer, POLE-mutated colorectal cancer, and broader gastrointestinal malignancies. His clinical work also covers biomarker-driven treatment selection and pharmacogenetics in GI oncology.
Submit your medical reports through CancerFax using the Send Your Reports button. The CancerFax team will review your case, prepare a structured summary, and coordinate the consultation with Asan Medical Center โ subject to availability and case acceptance. We handle scheduling and pre-consultation logistics.
A second-opinion request can be submitted through CancerFax with the patient's pathology reports, molecular profiling results (including RAS, BRAF, MSI status), imaging studies, and treatment history. Prof. Kim's assessment can include independent review of treatment sequencing, biomarker-guided options, and clinical trial eligibility. Final consultation format and availability depend on Asan Medical Center's scheduling.
Prof. Kim has extensive clinical and research experience in MSI-H and mismatch repair-deficient (dMMR) colorectal cancer. He is the responsible party for an Asan Medical Center-sponsored clinical trial of durvalumab in MSI-H or POLE-mutated metastatic colorectal cancer (NCT03435107), and his research includes contributions to KEYNOTE-177 Asian subgroup analysis โ pembrolizumab in first-line MSI-H metastatic colorectal cancer.
Yes. Prof. Kim is an active clinical trial investigator at Asan Medical Center. He is the responsible party for the durvalumab study in MSI-H or POLE-mutated metastatic colorectal cancer (NCT03435107). CancerFax can assess trial eligibility and coordinate case submission to Asan Medical Center where applicable, subject to trial availability and enrolment criteria.
Connect with Tae Won Kim Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.